asco@alo33:162179 JSONTXT

Background: In order to improve knoledge about treatment and outcome of breast cancer patients ith brain metastases BM e initiated the registry Brain Metastases in Breast Cancer Netork Germany BMBC, GBG79 . Methods: Patients diagnosed ith BM since 2000 ere included retrospectively and prospectively. 1105 patients from 54 centers ere analyzed. Results: Median age at diagnosis of BM as 51 years 20 87 years . 49.0 percent of patients 4721105 had HER2-pos., 20.5 percent 1981005 triple-neg. and 30.5 percent 2941005 luminal primary tumors. One year survival rate from diagnosis of BM as 35.7 percent CI95 percent: 32.6 38.8 . Median time from first diagnosis of BM to death in the entire cohort as 7.1 month CI95 percent: 5.8 7.9 . HER2-positive patients had the longest median survival ith 12.1 mo. CI95 percent: 10.2 13.7 compared to 5.5 mo. CI95 percent: 4.1 7.1 for luminal primary tumors and 4.1 mo. CI95 percent: 3.1 4.8 for triple-negative patients p lt 0.001 . Median OS of patients ith BM diagnosed beteen 2000 and 2006 as 7.2 mo. CI95 percent: 5.3 - 9.6 compared to 6.7 mo. CI95 percent: 5.5 -8.1 of patients diagnosed beteen 2007 and 2012 p = 0.848 . No relevant OS improvements ere observed in these time intervals for luminal 5.1 mo. [CI95 percent: 2.7-10.4] vs. 5.8 mo. [CI95 percent: 4.1 -8.0]; p = 0.541 , triple negative 4.6 months [CI95 percent: 3.3 -7.4] vs. 4.0 mo [CI95 percent: 2.4 - 5.4]; p = 0.558 or HER2-pos. patients 10.7 mo. [CI95 percent 7.7- 13.5] vs. 12.6 [CI95 percent 9.4 15.5]; p = 0.320 . 32.8 percent of HER2-pos. patients received HER2-directed therapies beyond the diagnosis of BM 55.5 percent trastuzumab, 53.5 percent lapatinib, 19.4 percent T-DM1 and 11.0 percent trastuzumab and pertuzumab . Those HER2-pos. patients receiving HER2-directed therapy after the diagnosis of BM lived longer than those ithout median 17.7, CI95 percent: 15.0 22.0 vs. 12.9 mo., CI95 percent: 10.5 17.1, p = 0.015 . Conclusions: Patients that received HER2-directed therapy after diagnosis of BM had an improved survival. Hoever, e could not observe improvement of survival over the study period in any tumor subtype. These findings underline the high need for the development of ne treatment strategies in patients ith BM from breast cancer.,J Clin Oncol 34, 2016 suppl; abstr 2070 00:00.0,Central Nervous System Tumors